Furthermore, the results of survival analysis showed that patients with ccRCC in the NEK2 high-expression group had a significantly shorter survival time than patients with ccRCC in the NEK2 low-expression group. This evidence concerns the gene NEK2 and nonpapillary renal cell carcinoma.